About
Approach
Investment Model
Investment Scope
Our approach
Team
Managing Partner
Partners
Venture Partners
Our team
Portfolio
News
Connect
Pages
Pages
Home
About
Blog
Blog Post
Contact
Portfolio
Investors
Investor Single
Shop
Shop Single
Utility Pages
Start Here
Style Guide
404 Not Found
Password Protected
Licenses
Changelog
Browse More Templates
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
Article Date
February 10, 2026
This article is featured on another website.
Go to article
Related posts
Browse all articles
February 26, 2026
Podcast featuring Jean-Marie Cuillerot, Chief Medical Officer at Kainova Therapeutics – Closing the gap on rare diseases in 2026
February 26, 2026
Podcast featuring Jean-Marie Cuillerot, Chief Medical Officer at Kainova Therapeutics – Closing the gap on rare diseases in 2026
January 26, 2026
Interview: Biosimilars, a market reaching an inflection point — a conversation with Frederic Bouvier
January 26, 2026
Interview: Biosimilars, a market reaching an inflection point — a conversation with Frederic Bouvier
